ArticleFrontiers in global women's health2026
Real-world treatment patterns in patients with dysmenorrhea in Japan: a retrospective database study.
Article in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysmenorrhea poses significant disease burden beyond menstruation pain but patients are known to be undertreated. Objective: To describe treatment patterns after the diagnosis of dysmenorrhea using health insurance claims data from insured members in Japan. Methods: We analyzed treatment patterns following the diagnosis of dysmenorrhea in women aged 18-45 years using health insurance claims from multiple Japanese health insurance societies between January 1, 2017 and September 30, 2022. We examined the first-line and subsequent treatment lines up to the third line treatments. Results: A total of 70,981 patients were identified, with a mean age of 29.7 years old. The most common first-line treatments and their median [interquartile range] durations were as follows: low-dose estrogen-progestin (LEP; otherwise known as combined oral contraceptive) in 33,169 patients (46.7%) for 161 [65, 384] days, analgesics/hemostatic agents (symptomatic therapy) in 13,619 patients (19.2%) for 9 [5, 29] days, and Kampo medicine (Chinese traditional herbal medicine adapted to and evolved in Japan) in 10,835 patients (15.3%) for 62 [29, 134] days. Across the treatment sequences from the first to third lines, LEP was the most frequently prescribed therapy. The most frequent pattern was LEP plus analgesics/hemostatic agents (18,019; 25.4%), followed by LEP monotherapy (10,389;14.6%), which collectively accounted for approximately 40% of all treatments. Analgesics/hemostatic agents alone accounted for 8,523 (12.0%) and Kampo medicine alone for 4,806 (6.8%). The transition from analgesics/hemostatic agents to LEP occurred in 2,166 (3.1%) of patients. Conclusions: An analysis of treatment sequences up to the third line revealed that LEP was the most commonly prescribed medication for dysmenorrhea. The median duration of LEP use exceeded five months, suggesting that many patients continued LEP across multiple menstrual cycles and that LEP was well accepted and sustained as a treatment for dysmenorrhea in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.